CART123 cells with or without ruxolitinib for AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (CART123) alone or with a drug called ruxolitinib for children and young adults with AML that has come back or not responded to standard treatment. The goal is to see if this combination can help destroy leukemia cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 1 and 29 years old (special rules for children under 12 in one group).
- Your AML must have returned after treatment or not responded to chemotherapy.
- You need to have a stem cell donor ready in case a transplant is needed after the study treatment.
- Your heart, lungs, liver, and kidneys must be working well enough (doctors will check).
- You must be able to get out of bed and take care of yourself most of the day.
- You cannot have active hepatitis B, C, HIV, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This Phase 1 trial tests an allogeneic immune-cell therapy for adults with CD123-positive acute myeloid leukemia (AML) that has not responded well to standard treatments. It aims to see whether this treatment can control leukemia after medicines and possibly transplant options are no longer suitable.
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
This trial tests a combination of CAR-T cell therapies (targeting CD123, CLL-1, and CD7) followed by a stem cell transplant for people with acute myeloid leukemia that has returned or not improved. The goal is to see if this approach can help eliminate the leukemia and prepare for a transplant.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.